drugset / Trial / NCT01202877
PKC412 and 5-Azacytidine
Phase 1/2
Completed
54 enrolled
M.D. Anderson Cancer Center
Celgene Corporation · collabNovartis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if the combination of PKC412 (also called Midostaurin) and 5-azacytidine can help to control refractory or relapsed acute leukemia and MDS. The safety and best dose of the combination of the drugs will also be studied.
Timeline
- Start
- 2011-03
- Primary completion
- 2015-07
- Completion
- 2015-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |
| Subject | Midostaurin | Small molecule | 50 mg | Oral |